Bio Path Holdings Stock Analysis

Bio Stock Analysis Notes

The book value of the company was currently reported as 0.71. The company recorded a loss per share of 8.34. Bio Path Holdings last dividend was issued on the 18th of January 2019. The entity had 1:20 split on the 23rd of February 2024. Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. For more info on Bio Path Holdings please contact the company at 832 742 1357 or go to https://www.biopathholdings.com.

Bio Path Holdings Investment Alerts

Bio Path Holdings Upcoming and Recent Events

Bio Largest EPS Surprises

View All Earnings Estimates

Bio Stock Institutional Investors

Note, although Bio Path's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Bio Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.44 M.

Bio Profitablity

Management Efficiency

Bio Path Holdings has return on total asset (ROA) of (1.4003) % which means that it has lost $1.4003 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6618) %, meaning that it created substantial loss on money invested by shareholders. Bio Path's management efficiency ratios could be used to measure how well Bio Path manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Path's current Return On Tangible Assets is estimated to increase to -4.74. The Bio Path's current Return On Capital Employed is estimated to increase to -11.45. As of now, Bio Path's Net Tangible Assets are increasing as compared to previous years.

Technical Drivers

As of the 22nd of November, Bio Path shows the Standard Deviation of 7.01, risk adjusted performance of (0.07), and Mean Deviation of 4.27. Bio Path Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Bio Path Holdings Price Movement Analysis

Bio Path Holdings Insider Trading Activities

Bio Path Outstanding Bonds

Bio Path Predictive Daily Indicators

Bio Path Forecast Models

Bio Path's time-series forecasting models are one of many Bio Path's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Bio Path's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Bio Path prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Bio shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Bio Path. By using and applying Bio Stock analysis, traders can create a robust methodology for identifying Bio entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Bio analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Bio analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Bio Path Holdings stock analysis indicators help investors evaluate how Bio Path stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Bio Path shares will generate the highest return on investment. By understating and applying Bio Path stock analysis, traders can identify Bio Path position entry and exit signals to maximize returns.

When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.